Quick Answer
Trevi Therapeutics, Inc. reported Common Stock Shares Outstanding of 128.31 million shares for the year ending 2025.
- Trevi Therapeutics, Inc. showed an increase of +37.1% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from Trevi Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 17, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: 438,600 shares | Q2 2019: 17.83 million shares | Q3 2019: 17.83 million shares | Q1 2020: 17.83 million shares | Q2 2020: 17.85 million shares | Q3 2020: 18.32 million shares | Q1 2021: 19.91 million shares | Q2 2021: 21.46 million shares | Q3 2021: 18.55 million shares | Q1 2022: 30.81 million shares | Q2 2022: 39.72 million shares | Q3 2022: 58.32 million shares | Q1 2023: 60.07 million shares | Q2 2023: 63.10 million shares | Q3 2023: 63.86 million shares | Q1 2024: 68.96 million shares | Q2 2024: 72.59 million shares | Q3 2024: 75.45 million shares | Q1 2025: 99.89 million shares | Q2 2025: 121.78 million shares | Q3 2025: 128.22 million shares.
- Over the full 8 years of available data (2018 to 2025), Trevi Therapeutics, Inc.'s Common Stock Shares Outstanding has grown by 29,153.5%.
- Historical annual values: Fiscal year 2025: 128.31 million shares | Fiscal year 2024: 93.60 million shares | Fiscal year 2023: 68.28 million shares | Fiscal year 2022: 59.94 million shares | Fiscal year 2021: 28.51 million shares | Fiscal year 2020: 18.55 million shares | Fiscal year 2019: 17.83 million shares | Fiscal year 2018: 438,600 shares.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: